secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2026-07-28T10:05:27+00:00
Accession:  0001104659-26-087269
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS reports positive blinded 6-month interim data for PMN310 in Alzheimer's Phase 1b trial
--------------------------------------------------------------------------------

- No ARIA-E observed across all genotypes; 4.4% total ARIA (all mild, asymptomatic ARIA-H) with no drug-related discontinuations.
- 61% of patients were APOE4 carriers (11% homozygotes); no ARIA-E in any genotype, including this high-risk group.
- 68.5% of patients had decline in plasma pTau217; 62.5% had decline in CSF MTBR-tau243, consistent with target engagement.
- Trial remains blinded; unblinded 12-month topline efficacy data expected in Q1 2027.
- PMN310 designed to selectively bind toxic amyloid-beta oligomers while avoiding plaque, aiming to decouple efficacy from ARIA risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/0001104659-26-087269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/pmn-20260728x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-087269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer